Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?

Dipesh H Vasant, Alexander C Ford

ORCID number: Dipesh H Vasant 0000-0002-2329-0616; Alexander C Ford 0000-0001-6371-4359.

Author contributions: Vasant DH and Ford AC both reviewed the literature; Vasant DH wrote the paper; Ford AC reviewed and helped write the paper, and provided important intellectual input.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: March 28, 2020  Peer-review started: March 28, 2020  First decision: April 18, 2020

Dipesh H Vasant, Gastroenterology, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester M23 9LT, United Kingdom

Dipesh H Vasant, Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester M23 9LT, United Kingdom

Alexander C Ford, Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds LS9 7TF, United Kingdom

Alexander C Ford, Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, United Kingdom

Corresponding author: Dipesh H Vasant, MBChB, MRCP, PhD, Senior Lecturer, Gastroenterology, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Southmoor Road, Manchester M23 9LT, United Kingdom. dipesh.vasant@mft.nhs.uk

Abstract

Recent advances in biological therapies have revolutionised and redefined treatment targets in inflammatory bowel disease (IBD). There is now a stronger emphasis on achieving the more stringent therapeutic goals of mucosal and histological healing, rather than clinical remission alone. Consequently, the treatment of refractory “functional” gastrointestinal symptoms, often attributed as the aftermath of previous inflammation, has recently become more prominent in quiescent disease. With further expected advances in anti-inflammatory treatments on the horizon, the burden of such symptoms in quiescent disease, which have been relatively neglected, is set to become an even bigger problem. In this article, we highlight the current state of research and understanding in this field, including recent developments and clinical practice guidelines on the diagnosis and management of functional gastrointestinal symptoms, such as irritable bowel syndrome and functional anorectal and pelvic floor disorders, in patients with quiescent IBD. These disorders are not only highly prevalent in these patients, they are often misdiagnosed, and are difficult to treat, with very few evidence-based therapies. Moreover, they are associated with substantial impairment in quality-of-life, considerable morbidity, and psychological distress. There is therefore an urgent need for a change in emphasis towards earlier recognition, positive diagnosis, and targeted treatment for patients with ongoing functional gastrointestinal symptoms in the absence of active IBD. This article also highlights the need for further research to develop much needed evidence-based
INTRODUCTION

Recent advances in medical therapies for both ulcerative colitis (UC) and Crohn's disease (CD) have improved the frequency and depth of remission in patients with inflammatory bowel disease (IBD)[6]. With the current availability of biological agents targeting multiple disease mechanisms including anti-tumour necrosis factor-α, anti-integrin, and anti-interleukin 12/23 drugs, as well as janus kinase inhibitors, the goals of IBD treatment have changed dramatically in recent years. Moreover, the introduction of several, more cost-effective, biosimilar drugs, have also improved access to some biological agents[3].

As a result of these developments, complete mucosal and histological healing, which appears to lead to improved outcomes for patients[2-5], has become a realistic therapeutic target. Consequently, clinical remission is no longer the recommended standard of care, and a more aggressive, “treat to target approach” , has been advocated[6]. This change in emphasis, together with the use of biochemical and endoscopic measures of subclinical inflammation to assess disease activity, has led to increasing awareness of a group of patients with IBD who have refractory gastrointestinal symptoms, in the absence of objective inflammation[6]. Indeed, recent data have shown that there is often a poor correlation between symptoms and mucosal inflammation in IBD[6]. Although the potential for co-existence of “functional” gastrointestinal symptoms in a proportion of patients with quiescent IBD was first described over 30 years ago[4,15], this group of patients has received minimal attention in the medical literature until relatively recently.

The pathophysiology of functional gastrointestinal disturbances in quiescent IBD is likely to be multifactorial, with numerous experimental studies demonstrating post-inflammatory changes in gut motility, permeability, impaired colocolonial function (abnormal colonic tone, rectal compliance and impaired anal sphincter function), and visceral hypersensitivity. With further progress in controlling inflammation successfully in patients with IBD anticipated, it is likely that there will be an even higher burden of refractory functional symptoms in IBD clinics in the future. However, despite overlap of functional symptoms being common in patients with IBD, there are limited evidence-based treatment options. This article discusses recent developments in this field, to highlight areas of unmet need, and suggest future directions and treatment paradigms.

The importance of early recognition and a positive diagnosis of functional overlap

Functional gastrointestinal disorders (FGIDs), are the most common disorders seen by gastroenterologists[16], affecting around 35% of the general population[17]. Based on their putative pathophysiology, these disorders have recently been re-defined as disorders...
of gut-brain interaction, and there is now an increased emphasis on making a positive diagnosis of the majority of these conditions, using symptom-based criteria, in the absence of red flag symptoms. In the general population, functional bowel disorders are the most common of these disorders of gut-brain interaction, affecting almost 30% of people and, interestingly, these conditions have a similar, or even higher, prevalence in the IBD clinic. Indeed, pooled prevalence data from a 2012 meta-analysis suggested a prevalence of symptoms compatible with irritable bowel syndrome (IBS) of 35% in quiescent IBD, with a higher prevalence in CD compared with UC.

The majority of studies included in this meta-analysis pre-dated the availability of faecal calprotectin (FC) as a non-invasive biochemical marker of gut inflammation and therefore reported the frequency of IBS-type symptoms in patients in clinical remission. However, even in subsequent studies that have used markers of biochemical remission, such as FC, mucosal remission, or histological remission the proportion of patients with IBD reporting these symptoms remains in the region of 25% to 30%.

Importantly, and consistently, these functional bowel symptoms in IBD are associated with significant psychological distress, and impair quality of life to a similar extent to that seen in patients with IBD with confirmed active gastrointestinal inflammation. Similarly, although even less well studied, functional anorectal disorders including evacuatory disorders and faecal incontinence, are often reported in patients with quiescent disease. In the absence of active inflammation, escalation of IBD therapy, including potentially inappropriate use of corticosteroids or immunosuppressive drugs is likely to be futile, leading to further patient dissatisfaction, costly, and carries the risk of serious adverse effects.

This underlines the importance of early recognition of functional gastrointestinal symptoms in patients with IBD.

Unlike the diagnosis of FGIDs in a non-IBD population, the diagnosis of overlapping FGIDs in IBD first requires some investigation, in order to exclude active inflammation. As recommended in a recently proposed diagnostic algorithm, a stepwise approach using biochemical tests including FC, followed by endoscopy and biopsies, or cross sectional imaging, should be followed. Although not the focus of the current paper, it is also important to consider and, where appropriate, exclude treatable mimics of FGIDs, such as bile acid diarrhoea, small intestinal bacterial overgrowth, or pancreatic insufficiency, particularly where there are risk factors such as ileal disease or a history of predisposing surgical intervention.

Following the exclusion of active inflammation and important potential mimics, careful consideration should be given to the likely mechanism of symptoms, based upon the predominant clinical features, and recognising that there are likely to be several perturbations contributing to the pathophysiology. In addition to the traditional IBD-focused clinical history, particularly in the absence of active inflammation and structural pathology, screening questions for positive diagnostic features of FGIDs and risk factors for pelvic floor dysfunction are important. These include IBS symptoms (abdominal pain, bloating, and altered bowel habit or stool form), obstructive defaecatory symptoms, including incomplete emptying, straining, features of overflow diarrhoea or impaction, and rectal digitation. The latter is an important clinical feature, which appears to be predictive of response to pelvic floor biofeedback. Faecal incontinence should also be specifically screened, for as it has been shown to be highly prevalent in patients with IBD, but may be underreported due to embarrassment on the part of patients. This approach will help identify those in whom pelvic floor and anorectal physiology investigations are appropriate.

### Current strategies for management of functional gastrointestinal disorders in IBD

One of the most important steps in managing overlapping FGIDs in this context is optimising the patient-provider relationship, providing clear, understandable explanations, and a positive diagnosis. This is likely to improve acceptance of the diagnosis, engagement with treatment, and also helps manage expectations, all of which are important in achieving a positive clinical outcome.

As highlighted in a recent expert review, there are very few randomised controlled trials or prospective studies on the management of functional gastrointestinal symptoms in IBD. Current practice is therefore largely empirical, and often based upon the central tenets of IBS management using dietary, pharmacological, or psychological approaches (Table 1). One of the interventions with some evidence in clinical trials, as well as in a blinded re-challenge study in quiescent IBD, is a diet low in fermentable oligo-, di-, or mono-saccharides, and polyols (FODMAPs). Further evidence for the low FODMAP diet in patients with quiescent IBD and co-existent functional gastrointestinal symptoms comes from recent
Table 1 Therapies empirically used to treat functional gastrointestinal symptoms in inflammatory bowel disease requiring validation in future clinical trials

| Treatment                                      | Gastrointestinal symptom(s) targeted                                      |
|------------------------------------------------|-------------------------------------------------------------------------|
| Low FODMAPs diet                               | Bloating, visceral pain, diarrhoea                                       |
| Anti-motility agents (e.g., loperamide, ondansetron) | Exaggerated gastro-colic reflex, faecal urgency, diarrhoea, faecal incontinence |
| Laxatives and pro-motility agents (e.g., prucalopride, linaclotide) | Slow colonic transit, constipation                                      |
| Antispasmodics                                 | Visceral pain, bloating                                                 |
| Gut-brain neuromodulators (e.g., antidepressants) | Visceral pain, faecal urgency, diarrhoea                                |
| Probiotics                                     | Bloating, altered bowel habit                                           |
| Pelvic floor biofeedback                       | Evacuatory dysfunction, faecal urgency, faecal incontinence             |
| Psychological interventions (e.g., hypnotherapy, cognitive behavioural therapy) | Visceral pain, bloating, altered bowel habit, non-colonic symptoms |

FODMAPs: Fermentable oligo-, di-, or mono-saccharides, and polyols.

trial data demonstrating a significantly greater improvement in gastrointestinal symptom scores and significantly higher rates of symptom relief after 4 wk of a low FODMAP diet, compared with a sham exclusion diet[57].

Unfortunately, there remains very little evidence for the efficacy of specific pharmacological therapies in this patient group. Current approaches include the use of laxatives, prokinetics, such as prucalopride in those with chronic constipation (often those with distal colonic disease or proctitis), antispasmodics, anti-diarrhoeal drugs, such as loperamide, or central neuromodulators, such as antidepressants[48]. Although the latter class of drugs are one of the mainstays for the treatment of abdominal symptoms in IBS[58], to date there has been only one randomised controlled trial in CD, which did not show any benefit of fluoxetine in preventing relapse of disease activity in patients with quiescent disease[59]. In another retrospective study, using tricyclic antidepressants, the authors demonstrated moderate improvement of residual symptoms despite “optimal” medical therapy, particularly in those with UC[60]. Despite the fact that certain probiotics appear beneficial in the induction and maintenance of UC in particular[60], their efficacy in patients with overlapping FGIDs and quiescent disease has not been evaluated specifically, and should be assessed in future clinical studies.

In patients with anorectal dysfunction, or pelvic floor dyssynergia confirmed on anorectal physiology, targeted pelvic floor physiotherapy and biofeedback therapy appear to be of benefit in several small uncontrolled studies[39,62-64], underlining the importance of screening for these conditions in the IBD clinic. Several psychological interventions have been shown to be of benefit in patients with IBS, including gut-directed hypnotherapy[65] and cognitive behavioural therapy (CBT)[58]. Although these interventions may also benefit some patients with IBD, there have been few studies to date, most of which have not been conducted in patients with co-existent functional gastrointestinal symptoms[66]. Although the long-term benefits are unclear, CBT may have a short-term role in improving depression and quality of life in patients with IBD, and hypnotherapy has been shown to be of benefit in only two small studies[66,67].

CONCLUSION

Co-existent FGIDs are common in IBD, and are often under recognised and difficult to treat. Clinicians specialising in IBD are likely to soon become victims of their own success; as treatments targeting inflammation continue to improve they are likely to see more functional gastrointestinal symptoms, as a consequence of prior inflammation, in their clinics. There is therefore the need for a paradigm shift in the approach to some patients with IBD. Previously, in the absence of active inflammation as a cause for their symptoms, patients were often given reassurance that their disease was quiescent, but little else in the way of explanation as to why they were experiencing these symptoms, or how they should be managed. With improvements in our understanding of FGIDs in quiescent IBD, it is essential that clinicians have a
positive, structured, approach to managing these patients. The recent American Gastroenterological Association clinical practice update and diagnostic algorithm has helped raise awareness of these issues, and provided some much needed recommendations as to how to approach this group of patients. There remains, however, an urgent need for evidence-based therapies, as most of the pharmacological treatment of these symptoms is empirical, and extrapolated from the IBS literature. At present, the key to successful management of FGIDs in IBD is recognition, early diagnosis, clear communication, avoidance of inappropriate escalation of IBD-related medications, and a careful and holistic clinical assessment to select appropriate patients for a low-FODMAP diet, and pelvic floor and physiology investigations. The latter, in the appropriate setting, may lead to targeted interventions such as biofeedback, which can improve symptoms as well as quality of life.

Future research should focus on developing specific evidence-based treatments for quiescent symptoms in IBD, based on the results of well-designed clinical trials. A forthcoming randomised study in the United Kingdom, funded by the National Institute for Health Research, has been designed to study the effectiveness of both dietary and pharmacological interventions in this setting. The study, a multi-arm multi-stage trial of a low FODMAP diet, amitriptyline, ondansetron, or loperamide, will include almost 500 patients with UC with ongoing diarrhoea, despite a FC < 250 mcg/g. It is anticipated that this trial will provide much needed evidence as to how best to manage this group of patients. In addition to identifying effective medical therapies, there is also a need to develop a better evidence-base for psychological and behavioural therapies, as well as pelvic floor interventions, with larger clinical trials in patients with quiescent IBD. An improved understanding of the mechanism of pelvic floor dysfunction in quiescent disease as a prelude to potential neuromodulatory therapies is also required.

REFERENCES

1 Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. Immune Netw 2017; 17: 25-40 [PMID: 28261018 DOI: 10.4110/in.2017.17.1.25]

2 Gulasci L, Pentik M, Renz F, Brodzsky V, Baji P, Vegh Z, Grese KB, Danese S, Peyrin-Biroulet L, Lakatos PL. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem 2019; 26: 259-269 [PMID: 28393687 DOI: 10.2174/0929867326666170406112304]

3 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Bucel OC, White L, Brain O, Keshaw S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016; 65: 408-414 [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598]

4 Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bastón I, Ferreiro-Iglesias R, Lorenzo A, Domínguez-Muñoz JE. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns Colitis 2016; 10: 13-19 [PMID: 26351360 DOI: 10.1097/cco.0000000000000159]

5 Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Van Assche G, Van Oye H, De Vos M, Hommes D, Schreiber S, Neimek E, Huang B, Zhou Q, Mendez P, Petersson J, Potterton J, Wallace K, Robinson AM, Thakkar RB, D’Haens G. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2018; 390: 2779-2789 [PMID: 29096949 DOI: 10.1016/S0140-6736(17)32641-7]

6 Colombel JF, D’Haens G, Lee WJ, Peterson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2020; 14: 254-266 [PMID: 31403666 DOI: 10.1093/cco/cco131]

7 Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Geary R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marble T, Martinez P, Mukhopadhyay P, Murdoch TB, Ordas I, Panaccione R, Riddeli RI, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Ansell S, Paine J, Bouguen G, O’Donnell S, Pariente B, Winer S, Hanauer S. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015; 110: 1324-1338 [PMID: 26301311 DOI: 10.1038/ajg.2015.223]

8 Ungaro R, Colombel JF, Lissoo T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol 2019; 114: 874-883 [PMID: 30082907 DOI: 10.14309/ajg.0000000000000113]

9 Meng J, Agrawal A, Whorvell PJ. Refractory inflammatory bowel disease—could it be an irritable bowel? Nat Rev Gastroenterol Hepatol 2013; 10: 58-61 [PMID: 22965430 DOI: 10.1038/nrgastro.2012.173]

10 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bhaloch MH, Hamlin PJ, Ford AC. Poor Correlation between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. Am J Gastroenterol 2016; 111: 541-551 [PMID: 27002800 DOI: 10.1038/ajg.2016.59]

11 Isagar B, Harman M, Kaye MD, Whorvell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983; 24: 190-192 [PMID: 6826101 DOI: 10.1136/gut.24.3.190]

12 Mawe GM. Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon. J Clin
Innov 2015; 125: 949-955 [PMID: 25729831] DOI: 10.1172/JCTJ76306]

13 Villanacci V, Bassotti G, Nascimbene R, Antonelli E, Cadei M, Fisogni S, Salerni B, Geboes K. Enteric nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil 2008; 20: 1009-1016 [PMID: 18492026 DOI: 10.1111/j.1365-2982.2008.01146.x]

14 Bassotti G, Antonelli E, Villanacci V, Salerni M, Coppola M, Annese V. Gastrointestinal motility disorders in inflammatory bowel diseases. World J Gastroenterol 2014; 20: 37-44 [PMID: 24415856 DOI: 10.3748/wjg.v20.i1.37]

15 Annese V, Bassotti G, Napolitano G, Usai P, Andriulli A, Vantраппен G. Gastrointestinal motility disorders in patients with inactive Crohn's disease. Scand J Gastroenterol 1997; 32: 1107-1117 [PMID: 9399591 DOI: 10.3109/00365529709002989]

16 Pehukuri K, Vapaatalo H, Korpela R. Even low-grade inflammation impacts on small intestinal function. World J Gastroenterol 2010; 16: 1057-1062 [PMID: 20205274 DOI: 10.3748/wjg.v16.i10.1057]

17 Bassotti G, Villanacci V, Nascimbene R, Cadei M, Fisogni S, Antonelli E, Corazza N, Salerni B. Enteric neuronal apoptosis in inflammatory bowel diseases. J Crohns Colitis 2009; 3: 264-270 [PMID: 21172285 DOI: 10.1111.j.1752-8578.2009.00604.x]

18 Vivinus-Nébot M, Frin-Mathy G, Bizouche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, Hébuterne X, Piche T. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2014; 63: 744-752 [PMID: 23878165 DOI: 10.1136/gutjnl-2012-304066]

19 Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. Gastroenterology 2017; 153: 723-731.e1 [PMID: 28601482 DOI: 10.1053.j.gastro.2017.05.056]

20 Mueller MH, Kreis ME, Gross ML, Becker HD, Zeitl TT, Jehle EC. Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn's disease. Br J Surg 2002; 89: 1027-1031 [PMID: 12155630 DOI: 10.1046/j.1365-2168.2002.02173.x]

21 Andersson P, Olaison G, Hullbök O, Boeyrd B, Sjödahl R. Increased anal resting pressure and rectal sensitivity in Crohn's disease. Dis Colon Rectum 2003, 46: 1685-1689 [PMID: 14668596 DOI: 10.1053/dcr.2002.304741]

22 Brochard C, Siproudhis L, Ropert A, Mallak A, Bretagne JF, Bouguen G. Anorectal dysfunction in patients with ulcerative colitis: impaired adaptation or enhanced perception? Neurogastroenterol Motil 2015; 27: 1032-1037 [PMID: 25940976 DOI: 10.1111/nmo.12588]

23 Loening-Baucke V, Metcalf AM, Shirazi S. Anorectal manometry in active and quiescent ulcerative colitis. Am J Gastroenterol 1989; 84: 892-897 [PMID: 2756906]

24 Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. Frontline Gastroenterol 2014; 5: 266-271 [PMID: 28839783 DOI: 10.1177/2050640613490267]

25 Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. Am J Gastroenterol 2018; 113: 86-96 [PMID: 29134969 DOI: 10.1038/s41596-017.421]

26 Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016 [PMID: 27144617 DOI: 10.1053/j.gastro.2016.02.032]

27 Mayoelli P, Mearin F, Azpirzu F, Anderson V, Barbara G, Coisetti M, Emmanuel A, Hungin APS, Layer P, Stanghellini V, Whorwell P, Zerbib F, Tack J. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterol J 2017; 5: 73-78 [PMID: 29026591 DOI: 10.1177/2050640617731968]

28 Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 1474-1482 [PMID: 22929759 DOI: 10.1038/ajg.2012.268]

29 Gracie DJ, Williams CJ, Sood R, Muntau S, Bhola M, Hamlin PJ, Ford AC. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2017; 15: 376-384.e5 [PMID: 27189912 DOI: 10.1016/j.cgh.2016.05.012]

30 Henriksen M, Hoivik ML, Jelsness-Jørgensen LP, Mourn B, IBSEN Study Group. Irritable Bowel-like Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results From a Population-based Study [the IBSEN Study]. J Crohns Colitis 2018; 12: 389-393 [PMID: 29186372 DOI: 10.1093/ecto-jej/jcyx12]

31 Fukuba N, Ishihara S, Tada Y, Oshima N, Moriya M, Iyaki T, Kawashima K, Kushiya Y, Fujishiro H, Kinoshita Y. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol 2014; 49: 674-680 [PMID: 24646420 DOI: 10.3109/00365521.2014.898084]

32 Nigam GB, Limdi JK, Handy S, Vasant DH. OWE-11 The prevalence and burden of Rome IV functional colorectal disorders in ulcerative colitis. Gut 2019; 68: A203-A204 [DOI: 10.1136/gutjnl-2019-BSGAbstracts.390]

33 Gracie DJ, Ford AC. Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation? Inflamm Bowel Dis 2017; 23: E4-E5 [PMID: 27930410 DOI: 10.1093/ibd/iix0984]

34 Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 2013; 38: 44-51 [PMID: 23668698 DOI: 10.1111/apt.1235]

35 Barratt SM, Leeds JS, Robinson K, Shah PJ, Lobo AJ, McAlindon ME, Sanders DS. Reflux and irritable bowel syndrome are negative predictors of quality of life in colicid disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23: 159-165 [PMID: 2117777 DOI: 10.1097/MEG.0b013e328342a547]
Vasant DH et al. Functional gastrointestinal disorders in IBD

36 Perera LP, Radigan M, Guilday C, Banerjee I, Eastwood D, Babygirija R, Massey BT. Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression. Dig Dis Sci 2019; 64: 1923-1928 [PMID: 30725303 DOI: 10.1007/s10620-019-05488-3]

37 Mavroudis G, Simrén M, Jonell Jäät B, Öhman L, Strid H. Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. Therap Adv Gastroenterol 2019; 12: 175628419827689 [PMID: 30815033 DOI: 10.1177/175628419827689]

38 Nigam GB, Limdi JK, Vasant DH. Current perspectives on the diagnosis and management of functional anorectal disorders in patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018; 11: 175628418816956 [PMID: 30774193 DOI: 10.1177/175628418816956]

39 Rezae A, Gu P, Kaplan GG, Pimentel M, Al-Darmaki AK. Dysysnergic Defecation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2018; 24: 1065-1073 [PMID: 29529194 DOI: 10.1093/ibd/izx095]

40 Nigam GB, Limdi JK, Hamdy S, Vasant DH. PTH-108 The hidden burden of faecal incontinence in active and quiescent ulcerative colitis: an underestimated problem? Gut 2019; 68: A87-A87 [DOI: 10.1136/gutjnl-2019-BSGAbstracts.167]

41 Ge P, Kaernig ME, Kaplan GG, Pimentel M, Rezae A. Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2018; 24: 1280-1290 [PMID: 29617820 DOI: 10.1093/ibd/izx109]

42 Limdi JK, Vasant DH. Anorectal Dysfunction in Distal Ulcerative Colitis: Challenges and Opportunities for Topical Therapy. J Crohns Colitis 2016; 10: 503 [PMID: 26619892 DOI: 10.1038/ecco-jcc/jcc.2017]

43 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39: 447-458 [PMID: 24444711 DOI: 10.1111/apt.12624]

44 Ford AC. Peyrin-Biroulet L. Opportunistic infections with anti-tumour necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108: 1268-1276 [PMID: 23649185 DOI: 10.1038/ajg.2013.138]

45 Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1051-1063 [PMID: 22613901 DOI: 10.1038/ajg.2012.89]

46 Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Boulinik Y, Gentre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease. Gut 2014; 63: 848-856 [PMID: 24201338 DOI: 10.1136/gutjnl-2014-305741]

47 Lewis JD, Scott FL, Brensinger CM, Roy JA, Osterrman MT, Mantani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Anti-tumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol 2018; 113: 405-417 [PMID: 29336432 DOI: 10.1038/ajg.2017.479]

48 Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol 2019; 17: 380-390.e1 [PMID: 30099186 DOI: 10.1016/j.cgh.2018.08.001]

49 Barros LL, Farias AQ, Rezae A. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol 2019; 25: 4414-4426 [PMID: 31496621 DOI: 10.3748/wjg.v25.i13.4414]

50 Patcharatruk T, Valestin J, Schmelz A, Schulze K, Rao SSC. Factors Associated With Response to Biofeedback Therapy for Dysysnergic Defecation. Clin Gastroenterol Hepatol 2018, 16: 715-721 [PMID: 29411138 DOI: 10.1016/j.cgjo.2017.10.027]

51 Vasant DH, Solanki K, Radhakrishnan NV. Rectal Digital Maneuvers May Predict Outcomes and Help Customize Treatment Intensity of Biofeedback in Chronic Constipation and Dysysnergic Defecation. Dis Colon Rectum 2017; 60: e2 [PMID: 27926570 DOI: 10.1093/dcr/dsx000]

52 Norton C, Dibley LB, Bassett P. Fecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis 2013; 7: e302-e311 [PMID: 23228710 DOI: 10.1016/j.crohns.2012.11.004]

53 Bartlett I, Nowak M, Ho YH. Reasons for non-disclosure of faecal incontinence: a comparison between two survey methods. Tech Coloproctol 2007; 11: 251-257 [PMID: 17676265 DOI: 10.1007/s10151-007-0360-2]

54 Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Muir JG, Gibson PR. Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn’s Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. Clin Transl Gastroenterol 2016; 7: e164 [PMID: 27077959 DOI: 10.1038/ctg.2016.22]

55 Gibson PR. Use of the low-FODMAP diet in inflammatory bowel disease. J Gastroenterol Hepatol 2017; 32 Suppl 1: 40-42 [PMID: 28264670 DOI: 10.1111/jgh.13695]

56 Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. J Crohns Colitis 2017; 11: 1420-1429 [PMID: 28525543 DOI: 10.1093/ecco-jcc/jmx073]

57 Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H, Levenez F, Pons N, Maziers N, Lomer MC, Ehrlich SD, Irving PM, Whelan K. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology 2020; 158: 176-188.e7 [PMID: 31586453 DOI: 10.1053/j.gastro.2019.09.024]
58 Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2019; 114: 21-39 [PMID: 30177784 DOI: 10.1038/s41395-018-0222-5]

59 Mikocka-Walus A, Hughes PA, Bampton P, Gordon A, Campaniello MA, Mavrangelos C, Stewart BI, Esterman A, Andrews JM. Fluoxetine for Maintenance of Remission and to Improve Quality of Life in Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial. *J Crohns Colitis* 2017; 11: 509-514 [PMID: 27664274 DOI: 10.1093/ecco-jcc/jjw165]

60 Iskandar HN, Cassell B, Kanuri N, Gyawali CP, Gutierrez A, Dassopoulos T, Ciobra MA, Sayuk GS. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. *J Clin Gastroenterol* 2014; 48: 423-429 [PMID: 24406434 DOI: 10.1097/MCG.0000000000000049]

61 Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Aliment Pharmacol Ther* 2017; 46: 389-400 [PMID: 28633751 DOI: 10.1111/apt.14203]

62 Vasant DH, Limdi JK, Solanki K, Radhakrishnan NV. Biofeedback therapy improves continence in quiescent inflammatory bowel disease patients with anorectal dysfunction. *J Gastroenterol Pancreatol Liver Disord* 2016; 3: 1-4 [DOI: 10.15226/2374-815X/3/2/00153]

63 Perera LP, Ananthakrishnan AN, Guilday C, Remshak K, Zadvornova Y, Naik AS, Stein DJ, Massey BT. Dysynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in remission. *Dig Dis Sci* 2013; 58: 3600-3605 [PMID: 24026401 DOI: 10.1007/s10620-013-2850-3]

64 Khera AJ, Chase JW, Salzberg M, Thompson AJV, Kamm MA. Gut-Directed Pelvic Floor Behavioral Treatment for Fecal Incontinence and Constipation in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2019; 25: 620-626 [PMID: 30452638 DOI: 10.1093/ibd/izy344]

65 Vasant DH, Whorwell PJ. Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence-base, practical aspects, and the Manchester Protocol. *Neurogastroenterol Motil* 2019; 31: e13573 [PMID: 30815936 DOI: 10.1111/nmo.13573]

66 Gracie DJ, Irvine AJ, Sood R, Mikocka-Walus A, Hamlin PJ, Ford AC. Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2017; 2: 189-199 [PMID: 28404134 DOI: 10.1016/S2468-1253(16)30206-0]

67 Ballo S, Keefer L. Psychological Interventions for Irritable Bowel Syndrome and Inflammatory Bowel Diseases. *Clin Transl Gastroenterol* 2017; 8: e214 [PMID: 28102860 DOI: 10.1038/ctg.2016.69]

68 Gracie DJ, Ford AC. Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge. *Clin Gastroenterol Hepatol* 2019; 17: 572-573 [PMID: 30678841 DOI: 10.1016/j.cgh.2018.08.039]
